Results 1 to 10 of about 27,437,097 (250)
Treatment Options for Hepatitis B [PDF]
Canadian Journal of Infectious Diseases and Medical Microbiology, 2007 Hepatitis B virus (HBV) is an enveloped DNA virus with a double-stranded circular genome that replicates through an RNA intermediate within the host hepatocyte (1,2). The virus infects the hepatocyte and is converted to covalently closed circular DNA, which serves as a template for viral replication.
Conly, JM, Johnston, BL
openaire +3 more sources
Taking Malawi's option B+ programme from a B+ to an A+
The Lancet HIV, 2018 In The Lancet HIV, Beth A Tippett Barr and colleagues present national estimates of early mother-to-child transmission (MTCT) of HIV and factors associated with early MTCT from the National Evaluation of Malawi’s Prevention of MTCT Program (NEMAPP) for the period 2014–16. Among HIV-exposed infants aged 4–12 weeks, the MTCT rate was 3·7% (95% CI 2·3–6·0)
Nora E, Rosenberg, Audrey E, Pettifor
openaire +3 more sources
Bulletin of the World Health Organization, 2014 To estimate the incremental cost over 5 years of a policy switch from the Option B to the Option B+ protocol for the prevention of mother-to-child transmission (PMTCT) of the human immunodeficiency virus (HIV).Data from cost studies and other published sources were used to determine the cost, per woman and per cohort (1000 breastfeeding and 1000 non ...
Lisa O'Brien +3 more
openaire +3 more sources
Antiviral options for the treatment of chronic hepatitis B [PDF]
Journal of Antimicrobial Chemotherapy, 2006 Hepatitis B virus (HBV) is an important cause of end-stage liver disease and hepatocellular carcinoma. Effective treatment can delay or prevent these outcomes. The decision to treat is based on the activity of liver disease and HBV replication status, and the likelihood of a long-term benefit.
Melissa K, Osborn, Anna S F, Lok
openaire +2 more sources
Emerging Treatment Options for B-Cell Lymphomas [PDF]
Journal of the National Comprehensive Cancer Network, 2015 As targeted therapy in B-cell lymphomas rapidly expands beyond anti-CD20 monoclonal antibodies, many newer types of agents are in various stages of development. During his presentation at the NCCN 20th Annual Conference, Dr. Andrew D. Zelenetz explored many of them, including the newer immunoconjugates, the Bruton's tyrosine kinase inhibitor ibrutinib,
openaire +2 more sources
South African Journal of Obstetrics and Gynaecology, 2012 The prevalence of HIV among pregnant women using public health services in South Africa is well documented. The prevalence rose steeply from 1990 through to 2003. Subsequently a plateau phase has been observed, with the national prevalence at 29 - 30%.
openaire +1 more source
Management of hepatitis B in pregnancy: Weighing the options
Cleveland Clinic Journal of Medicine, 2009 Maternal screening and active and passive immunoprophylaxis have reduced the perinatal, or vertical, transmission of hepatitis B virus (HBV) dramatically. Without immunoprophylaxis, chronic HBV infection occurs in up to 90% of children by age 6 months if the mother is positive for both hepatitis B surface antigen (HBsAg) and hepatitis B e antigen ...
William D. Carey, Tram T. Tran
openaire +2 more sources
Options for axisymmetric operation of MFTF-B [PDF]
, 1986 The flexibility of MFTF-B for axisymmetric experiments has been investigated. Interhcanging the axicell coils and increasing their separation results in an axisymmetric plug cell with 12:1 and 6:1 inner and outer mirror ratios, respectively. For axisymmetric operation, the sloshing-ion neutral beams, ECRH gyrotrons, and the pumping system would be ...
Fenstermacher, M. E. +2 more
openaire +2 more sources
GATA-3 locks the door to the B-cell option
Blood, 2013 In this issue of Blood, García-Ojeda et al demonstrate a key mechanism that drives T and B lymphocytes to divergent fates from early in their development.
openaire +5 more sources